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Abstract
Background: A vaccine is needed to control the spread of human immunodeficiency virus type 1 (HIV-1). An in vitro assay
that can predict the protection induced by a vaccine would facilitate the development of such a vaccine. A potential
candidate would be an assay to quantify neutralization of HIV-1.
Methods and Findings: We have used sera from rhesus macaques that have been immunized with HIV candidate vaccines
and subsequently challenged with simian human immunodeficiency virus (SHIV). We compared neutralization assays with
different formats. In experiments with the standardized and validated TZMbl assay, neutralizing antibody titers against
homologous SHIVSF162P4 pseudovirus gave a variable correlation with reductions in plasma viremia levels. The target cells
used in the assays are not just passive indicators of virus infection but are actively involved in the neutralization process.
When replicating virus was used with GHOST cell assays, events during the absorption phase, as well as the incubation
phase, determine the level of neutralization. Sera that are associated with protection have properties that are closest to the
traditional concept of neutralization: the concentration of antibody present during the absorption phase has no effect on
the inactivation rate. In GHOST assays, events during the absorption phase may inactivate a fixed number, rather than a
proportion, of virus so that while complete neutralization can be obtained, it can only be found at low doses particularly
with isolates that are relatively resistant to neutralization.
Conclusions: Two scenarios have the potential to predict protection by neutralizing antibodies at concentrations that can
be induced by vaccination: antibodies that have properties close to the traditional concept of neutralization may protect
against a range of challenge doses of neutralization sensitive HIV isolates; a window of opportunity also exists for protection
against isolates that are more resistant to neutralization but only at low challenge doses.
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Introduction
The infection of rhesus macaques by simian human immuno-
deficiency virus (SHIV) can be used as a model to study the effects
of active and passive immunization [1,2,3]. SHIV are chimeric
virus which have been engineered with the inner, structural
components of simian immunodeficiency virus (SIV) as well as the
enzymes required for replication in macaques. In the present
study, we have used SHIVSF162 where the envelope of HIV-1SF162
has been substituted for that of SIVmac239 [4]. This chimeric virus
has been passaged four times through rhesus macaques [5].
Passive transfer studies indicate that full protection can be
obtained with a human monoclonal antibody, IgG1 b12 and
challenge with SHIVSF162P4 by the intravaginal route [6].
However, complete protection required antibody concentrations
which could not reasonably be expected to be induced by available
vaccine candidates and current immunization strategies. Similarly,
reductions in peak viral load in HIV-1SF162 envelope-immunized
macaques primed with alphavirus replicon particles and boosted
with recombinant glycoprotein correlated with serum neutralizing
antibody titers against HIV-1SF162 pseudovirus in the TZMbl
assay [7].
In previous studies with sera from immunized macaques which
were fully protected against SHIV challenge [8], we could not
show any neutralization in standard assays against HIV which had
been prepared in human peripheral blood mononuclear cells (HIV
prepared in PBMCs=primary virus) [9]. Neutralization could
only be demonstrated if the incubation phase was extended.
However, assays with PBMCs as targets are not sufficiently precise
to quantify neutralization kinetics [10]. Assays with GHOST cells
offer greater precision [11]. GHOST cells are human osteosar-
coma cells which have been engineered to express green
fluorescent protein following infection with HIV or SHIV isolates.
The cells have also been engineered to display CD4 which is the
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as co-receptors. The fluorescent cells can be quantified using a
fluorescence activated cell scanner and represent a measure of the
number of infectious virus.
The aim of the present study was to quantify various parameters
of the neutralization reaction using sera from rhesus macaques
which had been immunized with HIV-1 envelope vaccine
candidates (immunogens and schedules are summarized in
tables 1 and S1). A further aim was to determine if the parameters
had any association with protection [12,13,14,15] when the
macaques were subsequently challenged with SHIVSF162P4. Assay
formats with the potential to predict protection are described.
Results
Neutralizing antibody titers show variable correlation
with protection
Some macaques were completely protected while others which
had equal or greater in vitro neutralizing antibody titers became
infected (Figure 1). Neutralization antibody titers in the 1/48/2
Table 1. Summary of sources of sera from immunogenicity trials in rhesus macaques.
Trial Group Immunogens Immunization (weeks) Challenge
1 1.1 Recombinant SF162 DV2 gp140 0, 6, 16, 36, 47 Intravenous: 50 TCID50
1.2 Recombinant SF162 DV2 gp140 0, 6
SF162 V3 linear peptide 16, 37, 47
19b and IgG1 b12 mimotope 16, 37, 47
1.3 Recombinant TV1 DV2 gp140 0, 6, 16, 36, 47
1.4 Recombinant TV1 DV2 gp140 0, 6
TV1 V3 peptide; 16, 37, 47
19b and IgG1 b12 mimotope 16, 37, 47
1.5 Controls
2 2.1 Recombinant 461, SF162 and TV1 gp140 0, 6, 16 Intrarectal: 1,800 TCID50
2.2 Recombinant 461, SF162 and TV1 gp140 0, 6
SF162 V3 cyclised peptide 6, 16
SF162 V2 linear peptide; IgG1 b12 mimotope 6, 16
2.3 Recombinant 461, SF162 and TV1 gp140 0, 6
TV1 V3 cyclised peptide 6, 16
MPER peptide; IgG1 b12 mimotope 6, 16
2.4 Controls
3 3.1 Recombinant 461, SF162 and TV1 gp140 0, 6, 16 Intrarectal: 1,800 TCID50
3.2 SF162 V3 cyclised peptide 0, 6
SF162 V2 linear peptide; IgG1 b12 mimotope 0, 6
Recombinant 461, SF162 and TV1 gp140 6, 16
3.3 TV1 V3 cyclised peptide 0, 6
MPER peptide; IgG1 b12 mimotope 0, 6
Recombinant 461, SF162 and TV1 gp140 6, 16
3.4 Controls
4 4.1 Adenovirus Ad5hr-89.6PDCFI gp140 0, 12 Intrarectal: 1,800 TCID50
Recombinant SF162 gp140 24, 36
4.2 Adenovirus Ad5hr-89.6PDCFI gp140 0, 12
VEE replicons encoding SF162 gp140 24, 36
4.3 Controls
5 5.1 VEE encoding SF162 DV2 gp140 0, 4, 12 Intrarectal: 120 MID50
Recombinant SF162 gp140 24, 36
5.2 VEE encoding MJ4 gp140 0, 4, 12
Recombinant MJ4 gp140 24, 36
5.3 VEE encoding SF162 DV2 and MJ4 gp140 0, 4, 12
Recombinant SF162 and MJ4 gp140 24, 36
5.4 Empty VEE replicons 0, 4, 12
Recombinant SF162 and MJ4 gp140 24, 36
5.5 Controls
doi:10.1371/journal.pone.0028974.t001
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PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28974Figure 1. Regression analysis of neutralizing antibody titer with infection after SHIVSF162P4 challenge of immunized rhesus
macaques. Macaques are challenged 8 weeks after the final immunization. Neutralizing antibody titer is the dilution of serum which gives a 50%
reduction in luciferase production in 1/48/2 TZM-bl cells with SHIVSF162P4 pseudovirus. Infection is quantified as the area under the plot of viral load
against time following challenge for individual macaques. Viral load was measured as log10 RNA equivalents per ml of plasma and time in weeks.
Regression lines are presented in the form: y=mx + c where y is the area under the viral load curve, m is the gradient, x is the neutralizing antibody
titer and c is the intercept. A, immunization trial 1; 6 weeks before challenge. Spearman r=20.5324, p=0.0338. m=24.09061.417, c=19.9063.776,
r
2=0.3729, p=0.0120. B, immunization trial 1; 2 weeks before challenge. Spearman r=20.4912 p=0.0534. m=24.38061.370, c=20.4663.588,
r
2=0.4221, p=0.0065. C, immunization trial 1; sera from some macaques not available at challenge. D, immunization trial 2; sera from some
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showed a variable capacity for predicting protection. This
variability was highest between immunization strategies: regression
coefficients varied between 20.03932 in trial 2 and 20.8456 in
trial four. In contrast, coefficients were relatively consistent at
different times prior to challenge within each trial. Subsequent
studies used sera, with neutralization titers of approximately 1 in
1,000 or greater, taken from the macaques two weeks before
challenge. This titer of neutralizing antibodies may be expected to
influence in vivo protection. Various scenarios can be proposed to
explain the variability in predictive capacity of the TZMbl assay.
Neutralizing antibodies may not themselves be protective but their
levels reflect some other, protective immune response. It is also
possible that the antibodies which are being detected at the highest
dilution with in vitro assays are not the ones which are protective in
vivo. We may need to quantify neutralization at lower dilutions.
Rates of neutralization can be quantified using GHOST
cells
GHOST cells fluoresce when infected with HIV-1 and can be
used to quantify individual infectiousevents. Neutralizationof HIV-
1SF162 by sera from immunized macaques in a/24/2 (for
explanation see Materials and Methods section) GHOST assays
was exponential (equal proportions of virus are neutralized per unit
of time following exposure to antibody.) Neutralization rates could
be distinguished at different serum dilutions (Figure 2A, C, E, G).
However, it is apparent that if the plots are extrapolated back to
zero time (=the intercept, where the line crosses the vertical or y-
axis), they do not pass through the origin (point 0, 0 where the
vertical and horizontal axes cross): there is significant neutralization
(.50%) without any incubation. As the virus is slow to bind to the
target cells, this neutralization may be the result of antibody binding
to free virions in the supernatant above the target cells.
Alternatively, the presence of cells may be obligatory and events
following the exposure of virus or virus-antibody complexes to
targets may determine the eventual extent of neutralization.
Level of neutralization increases as absorption phase is
extended
Exponential neutralization was also seen during the absorption
phase of a 1/b/2 GHOST assay (Figure 2B, D, F, H). An
absorption phase is required in any assay but by extrapolating the
plots back, the point at which they cross the vertical axis can give a
measure of the neutralization at zero time of absorption which also
corresponds with the end of the incubation phase.
Neutralization is not exponential during the incubation
phase
Plots where both incubation and absorption phases were varied
(Figure 3) indicate that there was a delay before the inactivation of
free virions enters its exponential phase (Figure 3 B, C, D).
Although neutralization with the serum of one protected rhesus
macaque appeared to be exponential (Figure 3A), when the serum
was diluted (Figure 3B), there was a delay. The intercepts of the
exponential phases of all three sera are close to the origin.
Neutralization rates do not correlate with protection
The neutralization parameters were determined using GHOST
cell assays for sera from protected (n=13) and infected (n=22)
macaques. It seemed reasonable that a neutralization titer of
approximately 1 in 1,000 or greater in the TZM-bl assay had the
potential to influence in vivo protection. There was no statistically
significant difference between the rates of neutralization (Figure 4
A, B) of sera from protected and infected macaques during either
the incubation (p=0.0788) or the absorption (p=0.7457) phases.
Similarly, the intercepts also showed no statistically significant
differences (p=0.1888 for the incubation phase and p=0.1125 for
the absorption phase (Figure 4 C, D).
Ratios of neutralization rates at different serum dilutions
are lower than expected
The ratio of the serum dilutions (e.g. 1 in 20 and 1 in 50 in
Figure 2) in the assays was 2.5. However, the ratios of the rates of
neutralization at any two serum dilutions were reduced below their
expected values for both the incubation (Figure 4E) and absorption
(Figure 4F) phases. There was no statistical significance between
the protected and infected macaques for the neutralization rate
ratios during the incubation phase. However, in marked contrast,
there were statistically significant differences between the neutral-
ization rates of the serum dilutions during the absorption phase for
individual macaques (Figure 2 F, H). The difference between the
absorption phase ratios for the protected and infected macaques
was statistically significant (Figure 4F; Figure 5). During the
absorption phase the ratio was one for the protected macaques
(Figure 2B, D; Figure 4F). An alternative presentation of the data
(Figure 5) also indicates that the dilution of serum from a protected
macaque has no influence on the rate of neutralization during the
absorption phase independently of its activity during the
incubation phase.
Neutralization of low doses of heterologous virus
Recognition that events during the absorption phase, in
addition to those due to the incubation phase of HIV-1
neutralization assays, produce significant effects leads to further
conjectures. Firstly, only a fixed number of viruses may be
completely inactivated before the target cells remove them or their
complexes from the mixture. This contrasts with the proportion of
virus which is expected to be inactivated in the reversible reaction
between antibody and free virions. Second, assays with formats
where the influence of events during the absorption phase is
macaques not available at 6 weeks before challenge. E, immunization trial 2; 2 weeks before challenge. Spearman r=0.07864, p=0.7806.
m=0.987562.445, c=5.33366.947, r
2=0.01239, p=0.6929. F, immunization trial 2 at time of challenge. Spearman r=20.03932, p=0.8893.
m=20.126963.035, c=8.41867.803, r
2=0.0001344, p=0.9673. G, immunization trial 3; sera from some macaques not available at 6 weeks before
challenge. H, immunization trial 3; 2 weeks before challenge. Spearman r=20.3056, p=0.2680. m=24.13462,888, c=20.3668.716, r
2=0.1362,
p=0.1759. I, immunization trial 3 at time of challenge. Spearman r=20.2987, p=0.2794. m=23.70562.806, c=17.9367.616, r
2=0.1182, p=0.2096.
J, immunization trial 4; 6 weeks before challenge. Spearman r=20.8456, p=0.0107. m=27.39561.217, c=25.2963.758, r
2=0.8602, p=0.0009. K,
immunization trial 4; 2 weeks before challenge. Spearman r=20.7910, p=0.0279. m=23.96761.236, c=12.1563.074, r
2=0.6319, p=0.0184. L,
immunization trial 4 at time of challenge. Spearman r=20.7910, p=0.0279. m=24.71061.449, c=13.5063.437, r
2=0.6377, p=0.0175. M,
immunization trial 5; 6 weeks before challenge. Spearman r=20.6537, p,0.0001. m=24.10560.7381, c=18.7762.43762.488, r
2=0.5161,
p,0.0001. N, immunization trial 5; 2 weeks before challenge. Spearman r=20.6925, p,0.0001. m=24.62960.7528, c=17.9462.079, r
2=0.5660,
p,0.0001. O, immunization trial 5 at time of challenge. Spearman r=20.6941, p,0.0001. m=24.98160.8182, c=17.8762.089, r
2=0.5610,
p,0.0001.
doi:10.1371/journal.pone.0028974.g001
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reveal neutralization activity against a wider range of isolates,
particularly those which are relatively resistant to neutralization.
Figure 2. Reductions in infectious titer following exposure of
HIV-1SF162 to sera from immunized rhesus macaque. Sera are
taken two weeks before challenge. Reductions in infectious virus are
calculated as ratio of the titer (Vt) at time t for the virus exposed to
serum from an immunized macaque divided by the titer (Vc) at the
same time for a control serum. The ratio is transformed to log10 (Vt/Vc).
Incubation and absorption phases are measured in hours. Data are
displayed as means with standard errors. Plots are regression lines with
95% confidence band. Solid squares: 1 in 20 serum dilution; solid
triangles: 1 in 50 serum dilution. Expected ratio of neutralization rates is
the ratio of the serum concentrations within an individual assay: 2.5. A,
Incubation plots of serum from protected macaque in treatment group
3.2 (Ratio=2.79; p=0.0004189); B, absorption plots from same
macaque (Ratio=0.88; p=0.7321); C, Incubation plots from protected
macaque in treatment group 4.1 (Ratio=2.40; p=0.01276); D,
Absorption plots from same macaque (Ratio=1.05; p=0.8763). E,
Incubation plots from infected macaque in treatment group 2.1
(Ratio=2.07; p,0.0001). F. Absorption plots from same macaque
(Ratio=1.97; p=0.00305). G, Incubation plots from infected macaque in
treatment group 2.3 (Ratio=2.52; p=0.00842). H. Absorption plots
from same macaque (Ratio=2.10; p=0.0002994).
doi:10.1371/journal.pone.0028974.g002
Figure 3. Incubation plus absorption plots of HIV-1SF162
neutralization with sera from protected macaques. Sera are
taken two weeks before challenge. Reductions in infectious virus are
calculated as ratio of the titer (Vt) at time t for the virus exposed to
serum from an immunized macaque divided by the titer (Vc) at the
same time for a control serum. The ratio is transformed to log10 (Vt/Vc).
Incubation and absorption phases are measured in hours. Data are
displayed as means with standard errors. Solid horizontal line
represents 50% neutralization. Triangles, diamonds and discs: regres-
sion lines for absorption plots following incubation for different
intervals. Some symbols are excluded to improve clarity. Intercepts
determined (straight dotted lines) giving reduction in virus titer when
absorption is zero (; end of incubation phase) and plotted as solid
squares. Regression line with 95% confidence band (curved dotted
lines). Open squares are data which have been excluded from
calculation of regression line. A. Macaque in treatment group 2.1: 1
in 40 dilution of serum: Reduction during incubation phase of log10
0.629260.02930 infectious doses per hour starting at log10 20.3948 to
20.1589 (95% confidence interval) infectious doses. r
2=0.9957;
p=0.0022 B. Serum from same macaque at 1 in 100 dilution: reduction
rate log10 0.556960.03193 infectious doses per hour starting at log10
20.3479 to 0.5284 infectious doses. r
2=0.9967; p=0.0365 C and D Sera
at 1 in 20 dilution from macaques in treatment group 3.2. Reduction
rate for C is log10 0.681260.04007 infectious doses per hour starting at
log10 20.5457 to 0.5541 infectious doses; r
2=0.9966; p=0.0374
Reduction rate for D is log10 0.494860.08753 infectious doses per hour
starting at log10 21.192 to 1.210 infectious doses; r
2=0.9697; p=0.115.
doi:10.1371/journal.pone.0028974.g003
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were selected and used in 4/24/2 GHOST assays against a range
of low doses of HIV-189.6 (Figure 6). None of the sera significantly
changes the gradient of its plot while results from seven are
sufficient to produce statistically significant intercepts (Table 2).
Although the intercepts are the parameter which achieves formal
statistical significance, this may not reflect the real situation. The
analysis requires that if the gradients of the plots are not
significantly different the data are pooled and a common gradient
calculated. This operation does not change the mid points of the
plots but can have a considerable influence on the intercepts.
Nevertheless, for at least two sera (Figure 6) the difference between
the gradients of their plots and controls is less than 5% while the
interval between the x-intercepts (points where plots cross the
horizontal axis) of their untransformed plots is more than 15
infectious doses. Thus, percentage neutralization increases from
low levels with relatively high doses of virus to reach 100% at the
lowest doses. It is likely that two neutralization mechanisms are
involved. These will be distinguished as virion-associated neutral-
ization producing a percentage reduction in virus titer following
events during the incubation phase and cell-associated neutraliza-
tion producing a fixed reduction due to events during the
absorption phase of the assay.
Discussion
The traditional concept of neutralization needs to be modified,
particularly for the more resistant HIV-1 isolates, in at least two
respects: the target cells are not just passive indicators of virus
infectivity but are actively involved in the neutralization reaction;
the number, rather than the proportion, of viruses inactivated is
the feature with more relevance to protection under the conditions
found in natural transmission. Both criteria influence the ability of
in vitro results to predict in vivo protection.
The traditional concept of neutralization is that antibody binds
to virus and inactivates it [16]. The results from the present and
previous studies [10,17,18] indicate that multiple steps are
involved in HIV-1 neutralization so that the virus-antibody
complex remains infectious. Antibody binds to the free virion
since neutralization increases as the incubation phase is extended.
Figure 4. Comparison of serum neutralization functional
properties between protected and infected immunized rhesus
macaques. Data are summarized in box and whisker plots of the
gradients of regression lines (neutralization rates: log10 (Vt/Vc) per hour)
and the intercepts (log10 (Vt/Vc) at time 0) with a 1 in 20 dilution of
serum. Also, the ratios of neutralization rates with different serum
dilutions (expected ratio=2.5) are displayed. The medians of protected
(n=13; open boxes) and infected (n=22; striated boxes) rhesus
macaques are compared by the Mann-Whitney non-parametric two
sample test. Neutralization rates during A, incubation phase
(p=0.0788) and B, absorption phase (p=0.7457) of neutralization
assay; intercepts during C, incubation (p=0.1888) and D, absorption
(p=0.1125) phase of assay; E, incubation ratios (p=0.3748) and F,
absorption ratios (p=0.0004).
doi:10.1371/journal.pone.0028974.g004
Figure 5. Regression lines of incubation ratios against absorp-
tion ratios. Regression lines are plotted for the protected (n=13; open
squares) and infected (n=22; triangles) immunized rhesus macaques.
Strictly speaking, as neither the incubation ratio nor the absorption
ratio can be considered the independent variable and neither has a
fixed value, a regression analysis is not legitimate. None the less, for the
reader’s convenience, we present linear regression lines in the form of
y=mx + c: Protected macaques: m=20.11960.061; c=1.29360.121;
r
2 =0.2557; p=0.0779. Infected macaques: m=0.28760.290;
c=1.09060.477; r
2=0.04685; p=0.3333. The gradients of the lines
are not statistically significantly different (p=0.1785). in contrast, the
intercepts are highly significantly different (p=0.0007586).
doi:10.1371/journal.pone.0028974.g005
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the target cells have a major influence on the number of virus
eventually inactivated. The reaction between virus and antibody is
generally considered to be reversible [16] so that at equilibrium a
proportion of virus will be inactivated. In contrast, the reaction
which follows the exposure of the complexes to target cells is
limited by the removal of the virus and complexes from the surface
of the cells. It seems likely therefore that a fixed number of virus
will be inactivated. In the present study, we have tried to separate
the virus-antibody complex and the cell-associated reactions. The
number of virions inactivated is small. Binding of HIV to GHOST
cells is slow relative to binding to human PBMCs [17] and is likely
to influence the neutralization reaction. Previous studies by
ourselves and others indicate that neutralization shows consider-
able variation when different target cells are used
[19,20,21,22,23,24,25]. The present study indicates that the target
cells have a decisive influence on the capacity of the in vitro assay to
predict in vivo protection.
Virus, antibody and target cells should be considered as a single
system. The combination which comes closest to the traditional
concept of neutralization is associated with in vivo protection:
antibody binds to a virus which is relatively sensitive to
neutralization; events which follow the binding of the complex
to a target cell inactivate the virus in a reaction which is
independent of the antibody concentration. In the present study,
antibodies from an immunized macaque may bind to the free
virions but if the reaction following exposure to target cells is
influenced by the antibody concentration, the virus can still
replicate in vivo. Virus replication in vivo may be slowed but
sterilizing immunity is not seen.
The variation in the capacity of the TZMbl assay [26,27,28,29]
to predict in vivo protection may be attributed to at least two of its
features: the 50% neutralization titer can not distinguish between
antibodies which inactivate the virus and those which can only
slow down virus replication or some other feature associated with
viral pathogenicity [17,30], for example the time taken for the
virus-antibody complex to be removed from the surface of the
target cell. Increasing concentrations of antibodies which can slow
down virus replication may reduce or delay the plasma viremia in
vivo but antibodies which completely inactivate the virus may be
required for sterilizing immunity. It is also possible that in vivo
protection is determined by the size of the virus inoculum.
There are two ways of quantifying in vitro reductions in virus
infectious titer. An aliquot of virus can be mixed with antibody and
incubated. Then, the virus which remains infectious can be
quantified. If 1,000 TCID50, for example, were reduced to 200,
then this represents 80% neutralization. In our previous studies
with human PBMCs [10,17,18] or lymphocyte-dendritic cell co-
cultures [9], we have used an alternative assay format. We diluted
the virus first and added aliquots of serum to the individual doses,
incubated the mixtures and determined which dilutions retained
infectivity. In this format we are determining the dilution of virus
which contains a single infectious dose. Under the equivalent
conditions to the example above the dilution originally containing
5 TCID50 would be reduced to 1 TCID50. This reduction can be
considered as 80% neutralization. However, it can also be a
reduction of 4 TCID50. The formats of the assays used in the
present study can distinguish between these two measures: for
example is 20 TCID50 reduced to 4 TCID50 (=80% neutraliza-
tion) or 16 TCID50 (=inactivation of 4 TCID50)? The present
study indicates that both percentage reductions and fixed measures
contribute to the neutralization reaction with primary isolates of
HIV-1. We speculate that antibody binds to the free virus during
the incubation phase influencing the percentage of virus eventually
inactivated; events during the absorption phase contribute to cell-
associated neutralization of a fixed number of virus. Assay formats
can be modified so that one measure can be magnified at the
expense of the other. Assays with a format measuring reductions in
the number of infectious virus may better predict the outcome of
human vaccine trials than percentage neutralization. A further
conjecture is that there is an interaction effect: antibody binding to
the free virus facilitates cell-associated neutralization. However,
Table 2. Neutralizing parameters for selected sera against low doses of the heterologous HIV-189.6 primary isolate.
Group Gradient{ Intercept" % neutralization1 Difference in x-intercepts#
Controls: 1.17960.063 223.3369.142
2.1 1.28560.086 230.33612.89 29.00 3.80
2.1 1.12960.112 239.76618.21** 4.07 15.6
Controls 1.07560.053 27.97566.153
5.1 1.02560.083 223.13610.64*** 4.65 15.1
5.4 0.900060.080 0.350069.340* 16.3 27.81
Controls 1.08060.100 27.903610.84
5.3 1.29960.137 22.963614.92** 220.3 25.03
5.4 1.10860.097 2.928610.56* 22.59 29.96
Controls 1.02360.122 22.080612.80
3.2 0.744960.087 2.99868.791** 27.18 26.06
3.1 1.30260.117 210.04612.04* 227.27 5.68
{Number of fluorescent cells/dose of infectious virus.
"Number of fluorescent cells (point where plot crosses vertical axis).
1Gradient of plot with serum from immunized macaque divided by gradient of plot with control serum expressed as a percentage.
#Dose of infectious virus (interval between points where plots for sera from immunized and control macaques cross horizontal axis).
Significant difference with controls:
***p,0.001;
**p,0.01;
*p,0.05.
doi:10.1371/journal.pone.0028974.t002
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aspect with the polyclonal sera induced following vaccination.
Quantifying individual infectious events was crucial to testing
the mathematical model proposed by Scott Layne [31] and his
colleagues for inhibition of HIV infection by soluble CD4. The
model shares some features with the explanations offered for the
results in the present article. In particular, both systems are a
mixture of competitive and irreversible reactions. The model is
described by four ordinary differential equations involving five
reaction rate constants: the rate of infection of HIV for a particular
cell type; the forward and reverse rates of CD4 binding to
envelope glycoprotein gp120; the rate of gp120 shedding from
virions; the rate of non-specific inactivation of HIV. For the most
part, the model meets its design criteria. However, discrepancies
between the expected and observed results indicated that some
further refinements were still required. The hypothesis was
formulated that when HIV virions were incubated in increasing
concentrations of soluble CD4 they reached a critical condition in
terms of the number of gp120 molecules available for infection. At
the same time, soluble CD4 had a threshold concentration for
inactivation. Experiments showed that below the threshold, virus
inactivation did correspond to the association constant of the
CD4-gp120 reaction so that inactivation rates were proportional
to soluble CD4 concentration. However, at higher concentrations
this relationship was lost and the virus entered a state where it was
unduly sensitive to inactivation. It may be speculated that sera
from immunized macaques which were not fully protected from
SHIV challenge, where the neutralization rate during the
absorption phase was also seen to increase with serum concentra-
tion, could not induce an equivalent effect. In contrast, antibodies
from the protected macaques may have reduced the availability of
envelope glycoporteins below a critical level. A further modifica-
tion of the model which is also pertinent to the present study was
to separate the rate of infection into rates for before (=incubation
phase) and after (=absorption phase) binding of virus to its target
cell. Nonetheless, despite these points of agreement, some caveats
also need to be acknowledged. The test of the model was
performed with virus which had been prepared in continuous cell
lines (=laboratory isolate). Since the work was published, the
relevance of primary isolates has been recognized. Isolates which
are grown in PBMCs (=primary cells) may better represent the
virus involved in natural transmission events. Primary and
laboratory isolates have different properties. In the present
context, the most relevant observation is that sera from volunteers
in human vaccine trials were able to neutralize laboratory isolates
but not primary isolates in conventional assays [32]. It may be that
the ratio of the critical level of available infection sites to the actual
number of physical sites is greater for the primary isolates. An
additional rider relates to the range of available target cells. A
detailed description of the molecular changes which follow virus
binding to its CD4 receptor has become available [33,34] since the
mathematical model was first formulated. These studies revealed
that changes in conformation of the envelope glycoprotein either
form, stabilize or reveal a site which is specific for a chemokine
receptor and acts as a co-receptor for HIV infection. It may be
that the density of these co-receptors, CCR5 for primary isolates
and CXCR4 for laboratory isolates, or even the receptor : co-
receptor ratio, on the target cells is the limiting factor within the
system [24].
Assays which simulate natural transmission events are more
likely to predict the outcome of human trials. The dose of virus
transmitted may vary with the route of transmission [35,36,37,38].
In particular, higher doses of virus may be transmitted where
blood is transferred as with intravenous drug users. Conversely,
low doses can be expected by the heterosexual route since natural
defense barriers reduce the effective dose of the inoculum.
Similarly, the relative resistance to neutralization of the transmit-
ted virus may also influence the results of in vitro assays and in vivo
protection [39,40,41,42,43]: transmission by intravenous or
intrarectal routes avoids natural barriers and may be less selective,
allowing more neutralization resistant isolates to infect. In the
present study, we have shown that antibodies raised to one subtype
B HIV-1 isolate (HIV-1SF162), by a vaccine which would be
acceptable for human use, can neutralize a relatively resistant
heterologous subtype B isolate (HIV-189.6) but only at low doses.
So far we have been able to demonstrate a qualitative effect of
neutralization with low doses of virus. For future studies, if we wish
to more accurately quantify the number of infectious virus
inactivated we need to refine the assays further. This would best
be done using monoclonal antibodies which are protective in vivo.
Protection has been demonstrated in the RV144 human trial but
was not associated with in vitro neutralization [44]. Volunteers in
this trial were at risk for HIV-1 infection by the heterosexual route
Figure 6. Neutralization of HIV-189.6 by sera from macaques
immunized with HIV-1SF162 immunogens. Low doses of the
relatively neutralization resistant, subtype B HIV-189.6 isolate were
incubated at 37uC for four hours with a 1 in 20 dilution of either a
control serum (open squares) or serum from a macaque (solid triangles)
immunized with HIV-1SF162 recombinant immunogens. (Open triangles
represent data sets close to background levels which have been
excluded from the analysis of regression lines). The mixture was then
added to GHOST cells and allowed to absorb for 24 hours. The cells
were washed and cultured for a further 24 hours. Results are plotted
with regression lines; parameters are given as means with standard
errors A. Controls: m=1.17960.063 fluorescent cells/infectious dose of
virus; ; c=223.3369.142 fluorescent cells; 95% confidence interval for
x-intercept=3.816 to 32.93 infectious virus doses; immunized macaque
from group 2.1: m=1.12960.112 fluorescent cells/infectious dose of
virus; c=239.76618.21 fluorescent cells; 95% confidence interval for x-
intercept=0.7662 to 58.31 infectious virus doses:. The difference
between the x-intercepts=15.6 infectious virus doses. The difference
between the gradients was not statistically significant (p=0.6896) so
that the data were pooled and a common gradient calculated: 1.16188.
The intercepts on the vertical axis are significantly different
(p=0.001359). B. Controls: m=1.07560.053 fluorescent cells/infectious
dose of virus; ; c=27.97566.153 fluorescent cells; 95% confidence
interval for x-intercept=25.086 to 17.81 infectious virus doses;
immunized macaque from group 5.1: m=1.02560.083 fluorescent
cells/infectious dose of virus; c=223.13610.64 fluorescent cells; 95%
confidence interval for x-intercept=0.3555 to 38.59 infectious virus
doses:. The difference between the x-intercepts=15.1 infectious virus
doses. The difference between the gradients was not statistically
significant: p=0.6064 so that the data were pooled and a common
gradient calculated: 1.05833. The intercepts on the vertical axis are
significantly different (p,0.0001).
doi:10.1371/journal.pone.0028974.g006
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the format outlined in the present study and using virus isolates
circulating in the area where the trial was performed may indicate
that neutralization can be demonstrated with sera from the trial
volunteers. Current SHIV challenge regimes in macaques involve
either a bolus [45] with a relatively high dose of virus or repeated
low dose challenge until all control macaques are infected [46].
The former has the merit that if protection is seen it is likely to be
specific for SHIV; the latter will probably detect an immunization
schedule which shows any protection. An alternative protocol
would be to titrate virus in immunized and control macaques: the
difference in titer would be the measure of protection. Such a
protocol could also objectively quantify vaccine efficacy although
the number of heterologous virus against which protection can be
demonstrated may be too small for this approach to be practicable.
Materials and Methods
Ethics statement
The study involved a retrospective analysis of samples from five
immunogenicity trials involving 112 adult rhesus macaques,
weighing between 4 and 9 kg body and housed at the Biomedical
Primate Research Centre (BPRC), The Netherlands. The trials
included challenge with SHIVSF162P4. The trial protocols were
approved (permit numbers DEC#460, DEC#504, DEC#515,
DEC#520 and DEC#527) by the Committee on the Ethics of
Animal Experiments of Biomedical Primate Research Centre,
Animal Welfare Assurance Number VVP/V 9513. The qualifi-
cation of the members of this committee including their
independence from a research institute is requested in the Wet
op de Dierproeven (1996). All projects were monitored by a
qualified, independent veterinarian, specifically regarding the
ethical issues of the projects.
The use of non-human primates in The Netherlands is legalized
based on the law: ‘‘Wet op de Dierproeven’’ and adaptations as
published in the Staatscourant (48 (1975); 336 (1985); 585 (1992);
435 (1993); 806 (1994); 137(1996); 138(1996); 139 (1996); 5 (1997)
and the EU guidelines 86/609/EEG. These laws guarantee the
qualification of researchers, veterinary staff and animal caretakers
involved in experimental studies and breeding of non-human
primates. All animals were either from the breeding stock of the
BPRC or purchased from breeding centers in Asia. Identification
of imported macaques was confirmed by CITES. The accommo-
dation of laboratory animals was in accordance with animal
welfare requirements (1993); Wet op de dierproeven (WOD 1996);
Gezondheids-en welzijnswet (GWWD 1996). The animal facilities
were licensed to perform studies with genetically modified
organisms up to DM3 level (Law on Genetically Modified
Organisms, GMO law nr 108, 1996).
All steps were taken to ameliorate the welfare and to avoid the
suffering of the animals. At the start of a trial, all animals were in
good health and met with the following criteria: no previous
immunosuppresive treatment; negative for simian T-lymphotropic
virus, simian retrovirus and simian immunodeficiency virus (SIV);
low or no IFN-c, IL2 or IL4 responses against HIV env, gag, pol
or nef antigens. They were housed in adjoining, single primate
cages, because of the risk of cross-infection following challenge
with SHIV. Animals could interact socially with their neighbors
and had auditory and visual contact with others in the same room.
Enrichment was provided in the form of pieces of wood, mirrors,
food puzzles, variety of food and other home made or
commercially available enrichment products. The facility was
under controlled conditions of humidity (60%), temperature (23–
25uC) and lighting (12 hour light/dark cycles). Animals were fed
with standard food pellets, fruit and bread. Water was provided ad
libitum. Animals were sedated with ketamin before blood taking
and SHIV challenge. The number of monkeys to be used in
individual trials was reduced to a minimum by statistical power
calculations and variance values from previous studies to calculate
the minimal group sizes to give statistical significance.
At the BPRC all animal handling is performed in the
Department of Animal Science (ASD) according to the laws as
described above. At the BPRC a large experienced staff is
available including full time veterinarians and pathologists. The
ASD is regularly inspected by the responsible authorities (VWA)
and an independent Animal Welfare Officer.
An outline of the immunization schedules is given in tables 1
and S1. All schedules included an HIV-1SF162 envelope glycopro-
tein immunogen [47,48,49,50]. Macaques in immunogenicity
trials one, two and three were immunized in prime boost strategies
involving recombinant glycoproteins and synthetic peptides. In
trials 4 [51] and 5, the macaques were primed with immunogens
in vectors: a replicating adenovirus in trial four and an alphavirus
replicon in trial five. All macaques were challenged with
SHIVSF162P4 grown in rhesus macaque peripheral blood mono-
nuclear cells.
Virus isolates
Primary HIV-1SF162 (original donor: J. Levy [52] and HIV-189.6
(original donor: R. Collman [53]) were obtained from the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, Washington DC, USA. The stock was prepared in
phytohemagglutinin-transformed, recombinant human IL2 main-
tained human peripheral blood mononuclear cells (PBMCs).
Human PBMCs were donated by volunteers to the Stichting
Sanquin Bloedvoorziening, Rotterdam.
Neutralization assays
All neutralization assays are described as a/b/c where a is the
time in hours (=incubation) during which antibody and virus are
incubated prior to exposure to target cells (=absorption) for b
hours. The cells are then washed and incubated for c days
(=culture). The culture phase is timed form the cells’ first
exposure to virus. All three incubations are at 37 uC. All sera are
heat inactivated at 56 uC for one hour.
GHOST(3) Hi-5 cells are human osteosarcoma cells which have
been engineered to express the CD4 receptor and green
fluorescent protein following infection with HIV-1. The cell line
was obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH from Dr.
Vineet N. KewalRamani and Dr. Dan R. Littman [54]. The cells
have been engineered and selected for high expression of CCR5,
the co-receptor for the HIV-1 isolates used in this study. The
number of individual infectious events can be quantified using a
fluorescent activated cell scanner. For GHOST neutralization
assays a fixed dilution of each virus stock was chosen based on the
results of a previous titration: for neutralization kinetics studies the
virus dilution was chosen to give between 200 and 3,000
fluorescent cells per 10,000 recorded events. At higher doses
some cells are infected with more than one infectious virus. The
dose of virus was adjusted in accordance with the Poisson
distribution. One hundred and ninety mls of the fixed virus dilution
were incubated for a given interval (=a hours) with 10 mls of a
serum dilution at 37 uC. The virus-antibody mixture was added to
GHOST cells which had been seeded 24 h previously at 6610
4
cells per well in 24-well cell culture plates [11]. After an absorption
period (=b hours) the cultures were washed three times and
cultured for a total of two days (=c). i. e. the culture period is
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additives are used to enhance virus binding to target cells.
Subsequently, the cells were removed from the plastic by 1 mM
EDTA and fixed in formaldehyde at a final concentration of 1%.
The cells were analyzed with a FACSsortH flow cytometer (Becton
Dickinson). The cells were gated on the basis of forward and side
scatter. Using these parameters, uninfected cells were further gated
on fluorescence to set the upper limit of the region. The number of
infected cells was then determined using the gates with the
uninfected cells. The virus titer following incubation with antibody
is divided by its titer following incubation as free virus and plotted
on a log scale against the incubation (a) or absorption (b) time.
Neutralization kinetics were determined with sera at two
dilutions where the ratio was 2.5: 1 in 10 and 1 in 25; 1 in 20
and 1 in 50; 1 in 40 and 1 in 100; 1 in 50 and 1 in 125; 1 in 100
and 1 in 250.
For the standardized and validated neutralization assays the
TZM-bl cell line was used [55,56]. It was obtained through the
NIH AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH from Dr. John C. Kappes, Dr. Xiaoyun
Wu and Tranzyme Inc. This HeLa cell line is adherent and has
been engineered to express CD4 and CCR5 receptors. Following
infection with SHIVSF162P4 pseudovirus (constructed at the BPRC)
the cells produce luciferase, the activity of which can be detected
by luminescence. Sera were diluted to give a 1 in 20 dilution and
subsequently in a threefold series to a final dilution of 1 in 43,740.
Each dilution was mixed with sufficient pseudovirus to give
500,000 counts per second in a Perkin-Elmer (Groningen, The
Netherlands) Victor 6016971 luminometer. The mixture includes
15 mg/ml of DEAE and is then incubated for one hour before
10,000 TZM-bl cells are added. The cells are cultured for
48 hours, the supernatants removed and the cells lysed. The cell
lysates are transferred to black/white plates, Britelite reagent
added and the luciferase activity quantified. Antibody titers are
expressed as the dilution of serum required to reduce the luciferase
activity in cultures exposed to pseudovirus alone by 50%
[26,27,28].
Viral load determinations
For the first, second and third immunization trials the plasma
virus load was determined by a quantitative competitive reverse
transcription-PCR. Viral RNA was coamplified with a calibrated
amount of internal-standard RNA which was added prior to RNA
purification. As the target sequence, a highly conserved 267-base
pair region in the SIV gag gene was chosen. The internal standard
was based on the same 267-bp target sequence; however, by PCR,
the 26-bp probe region was replaced by a rearranged 26-bp
sequence. This fragment was cloned into a transcription vector,
and in vitro transcripts were synthesized by using T7 RNA
polymerase. The RNA was reverse transcribed and amplified
within one reaction protocol by rTth DNA polymerase (Perkin-
Elmer, Groningen, The Netherlands), using biotinylated primers.
The amplification products were alkaline denatured and hybrid-
ized in six fivefold dilutions to a capture probe that was covalently
bound to microwells. The products were detected by a
streptavidin-horseradish peroxidase-mediated calorimetric reac-
tion. The amplified internal standard was hybridized to a different
capture probe in separate microwells. The amount of RNA in the
plasma sample was determined by calculating the ratio of the
optical densities of the sample well and the corresponding internal-
standard well. Detection limit is 40 RNA copies/ml [57].
For the fourth and fifth immunization trials SHIV viral loads
were determined using an adapted version of a published SIV-gag-
based real-time PCR assay [58]. The SIV-probe used was identical
to the probe described [58] except that we used the quencher dye
Black Hole Quencher 2 instead of TAMRA. The forward (SIV31)
and reverse (SIV41) primers were essentially identical to primers
SIV.510f and SIV.592r [58], with minor modifications to improve
the sensitivity of the assay. The SIV31 and SIV41 primer
sequences were 59-CCAGGATTTCAGGCACTGTC-39 and 59-
GCTTGATGGTCTCCCACACA-39, respectively. The PCR
was carried out using the BrilliantH QRT-PCR Core Reagent
Kit, 1-Step (Stratagene Europe, Amsterdam, The Netherlands) in
a2 5 ml volume with final concentrations of 160 nM for each
primer, 200 nM for the probe, 5.5 nM MgCl2, and using 10 ml
RNA. RNA was reverse transcribed for 30 min at 45 uC. Then,
after a 10 min incubation step at 95 uC, the cDNA was amplified
for 40 cycles, consisting of 15 s denaturation at 95 uC, followed by
a 1 min annealing-extension step at 60 uC. All the reactions were
carried out with an iQ5
TM Multicolor Real-Time PCR Detection
System (Bio-Rad Laboratories BV, Veenendaal, The Nether-
lands). Detection limit is 100 RNA copies/ml.
Statistics
Statistical analyses were performed using GraphPad Prism
version 4.00 for Windows, GraphPad Software, San Diego,
California, USA, www.graphpad.com. All calculations were
performed to four significant figures and then adjusted to three
decimal places. Regression coefficients and probability values are
given to four significant figures.
Plots of the area under the viral load curve against the
neutralizing antibody titer in the TZM-bl assays (Figure 1) were
analyzed by linear regression. Regression lines are recorded as
y=mx+ c where m is the gradient and c the intercept (the value of
y when x=0). Scatter plots were also analyzed by the non-
parametric Spearman’s rank correlation test. The coefficient of
determination (r
2) gives the proportion of the variability in the
dependent variable (in this case the area under the viral load
curve, plotted on the vertical, y-axis) which can be attributed to the
independent variable (the neutralizing antibody titer, plotted on
the horizontal, x-axis). One macaque in the fifth trial was not bled
at week 2 and so was excluded from the analysis.
Neutralization rates (Figures 2 and 3): The rate of neutralization
with primary isolates of HIV-1 is relatively slow in comparison to
other viruses. We chose therefore to present neutralization rates in
terms of log10 reductions in infectious virus titer per hour rather
than the customary loge reductions per second. Plots are presented
as the regression line with its 95% confidence band.
Neutralization function comparisons (Figure 4): Data were
tested to determine if they followed a normal distribution by the
Kolmogorov-Smirnov test, D’Agostino and Pearson omnibus
normality test and the Shapiro-Wilk normality test. As many of
the samples failed one or other of these tests the data presented in
figure 4 are analyzed using the non-parametric Mann-Whitney
two-sample test. The ratio data are also presented as linear
regression plots in figure 5.
Plots of virus dose against numbers of fluorescent cells were
analyzed by linear regression (Table 2 and Figure 6). The
gradients of virus incubated with either a control serum or a serum
from an immunized macaque were then compared. If there was no
significant difference between the gradients, a gradient was
calculated from the pooled data and the resulting intercepts of
the plots compared.
SHIVSF162P4 challenge (see Table S1): immunization strategies
were compared using read-outs of peak viral load at week 2 and
the areas under the plot of viral load vs time after challenge by a
one-way analysis of variance (ANOVAR) or the non-parametric
Kruskal-Wallis test. Viral loads at each time point were also
Correlating Protection Induced by HIV-1 Vaccines
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differences between immunization strategies was determined by
Dunnett’s Multiple Comparison Test (one-way ANOVAR),
Dunn’s Multiple Comparison Test (non-parametric test) or
Bonferroni post tests (two-way ANOVAR).
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macaque immunogenicity and SHIVSF162P4 challenge studies.
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